Abstract
Cardiovascular disease (CVD) is closely associated with sarcopenia. We aimed to examine the relationship between Life’s Essential 8 (LE8) and the incidence of sarcopenia among adults in the United States. In this study, a cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey from 2013 to 2018 and included 5999 adult participants. LE8 score was categorized into low (< 49), moderate (49–79), and high CVH (≥ 79) groups and consisted of health behavior score and health factor score based on American Heart Association definitions. Sarcopenia was defined according to The Foundation for the National Institutes of Health Sarcopenia Project. Multivariate logistic regressions, restricted cubic spline regressions, and subgroup analyses were used to assess the association between LE8 and sarcopenia. LE8 and its subscales score were negatively associated with the incidence of sarcopenia in US adults.
Similar content being viewed by others
Introduction
Sarcopenia is the age-related loss of skeletal muscle mass and functions as a strong predictor of adverse health outcomes, including a higher risk of falls, fracture1,2, physical disability3, metabolic impairments4 and increased mortality5. The prevalence of sarcopenia among people aged 60–70 years old is reported to be 5–13%, but it increases to 11–50% in people older than 806. It is becoming a major public health problem7. With increasing age, tissue is confronted with less muscle protein and more fat mass8. Furthermore, genetics9, nutritional status10, physical activity11 and selective mortality12 are the risk factors for sarcopenia. Additionally, sarcopenia is also associated with respiratory disease13, cognitive impairment14, and cardiovascular disease15. Studies found that sarcopenia is an important risk factor for CVD16 and interestingly, CVD, in turn, can accelerate the process of sarcopenia17. Increasing evidence demonstrate the close relationship between sarcopenia and CVD.
In contrast to Life’s Simple 7 (LS7) score proposed by the American Heart Association (AHA) in 2010, LE8 score, an updated quantification algorithm in 2022, added sleep health18 element and updated definitions and scores for the previous 7 components (diet, physical activity, nicotine exposure, body mass index, blood lipids, blood glucose, and blood pressure)18 to quantify cardiovascular health (CVH). In the past decade, there is substantial evidence that LS7 has some imitations on the assessment of healthy lifestyles in modern burdensome social environments and different individuals18. Compared with LE7, LE8 is more sensitive to interindividual differences and intraindividual variations18.
Given extensive evidence indicating the close association between CVD and sarcopenia, LE8, the assessment tool for quantification of CVH may be a potential evaluation criterion for the risk of sarcopenia. As yet, no study has investigated the relationship between LE8 and sarcopenia. Therefore, this study aimed to assess the association between LE8 and sarcopenia using the available National Health and Nutrition Examination Surveys (NHANES) data. We hypothesized that sarcopenia and LE8 score have a dose–response relationship and participants with sarcopenia have a lower LE8 score than the nonsarcopenic.
Materials and methods
Study design and participants
NHANES is a survey designed to examine the health and nutritional status of the population in US involving interviews and physical examinations. The survey has been conducted in 2-year cycles from 1999 to 2000 and 3 cycles conducted from 2013–2014 through 2017–2018 were used in this study. These data were publicly available on the NHANES official website (http://www.cdc.gov/nchs/nhanes.htm) (accessed on September 18, 2023). Each cycle is independent with different individuals recruited and written informed consent was obtained from every participant.
The total combined sample of NHANES 2013–2018 comprised 29,400 participants and 17,057 participants aged 20 years old and above were included. We excluded participants with incomplete information for sarcopenia (n = 10,564), all 8 LE8 metrics (n = 493), and education levels (n = 1). The final study population included 5999 participants.
Measurement of LE8
The LE8 score includes health behaviors (diet, physical activity (PA), nicotine exposure, and sleep health) and health factors (body mass index (BMI), blood lipids, blood glucose, and blood pressure)18. Each component metric is scored on a scale of 0 to 100 and the total LE8 score is calculated as the average of the 8 components. Detailed algorithms of LE8 score have been published and can be found in the Journal of Circulation18. Four metrics of health behaviors are collected by self-reported questionnaires and components of health factors are measured with physical examinations. Diet metric was measured by self-reported daily intake and the scores were calculated using data from two 24 h dietary recalls and evaluated by the Healthy Eating Index (HEI) 201519. Physical activity scores were calculated based on the frequency, duration, and intensity of activity per week from self-report questionnaires. Nicotine exposure included inhalational nicotine delivery systems use or secondhand smoke exposure. Sleep health scores were measured by average hours of sleep per night. Additionally, BMI was calculated as the weight in kilograms divided by height in meters squared (kg/m2). Blood specimens from participants were used to measure blood parameters, such as blood lipids, fasting blood glucose, and hemoglobin A1C, through high-performance liquid chromatography or enzymatic assay. Blood pressure was measured after resting quietly in a sitting position for 5 min in the mobile examination center (MEC) and the average of three consecutive blood pressure measurements were used for analysis.
Measurement and definition of sarcopenia
According to guidelines, the diagnosis of sarcopenia depends on the physical examinations. Appendicular lean mass (ALM), the sum of lean mass in the arms and legs, was measured using dual-energy X-ray absorptiometry (DXA). DXA was performed on individuals by Hologic Discovery model A densitometers (Hologic, Bedford, Massachusetts, USA). A value of ALM standardized to BMI (ALMBMI) was used to define sarcopenia20 based on the criteria designated by a recent consensus meeting known as the “Foundation for the National Institutes of Health Sarcopenia Project”. Men were considered to have sarcopenia if the index ALMBMI < 0.789 and women < 0.51221.
Covariates
The information regarding demographic characteristics and lifestyle components was collected from questionnaires released by NHANES. In this study, age was stratified into two strata: 20–39 years or ≥ 40 years. Race included four categories: Mexican American; non-Hispanic white; non-Hispanic black, and others. Family poverty income ratio (PIR) was categorized as low (PIR < 1.3), medium (PIR = 1.3–3.5), and high (PIR > 3.5). Education level was categorized as Less than 9th grade, 9th to 11th grade, High school graduate, Some college and College graduate or above. Marital status was categorized as married/living with a partner or others and home status was classified as rented, owned/being bought, or others. Smoking status was categorized as never smoked, current smoker, or former smoker. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, diagnosed by a doctor, or use of prescription for hypertension. Coronary heart disease was defined as diagnosed by a doctor. Diabetes was defined as glycated hemoglobin HbA1c ≥ 6.5%, fasting glucose ≥ 7 mmol/L, random blood glucose ≥ 11.1 mmol/L, 2-h OGTT blood glucose ≥ 11.1 mmol/L, diagnosed by a doctor, or use of diabetes medication or insulin.
Statistical analysis
Because of the complex sampling design of NHANES, all data analyses considered sampling design and sampling weight to represent all US population22. This study combined the NHANES cycles from 2013–2014 through 2017–2018 and proper weights were used for weighted analysis. Continuous variables were summarized as means and standard deviation and analyzed using the Mann–Whitney U test or the student’s t-test. Categorical variables were presented as frequencies and percentages and compared using the chi-square test. Multivariable logistic regression models were used to determine the OR and 95% CI for the relationship between LE8 scores and sarcopenia. Model 1 was adjusted for age, race, and gender. Model 2 was adjusted for the factors included in model 1 and PIR, education levels, marital status, and home status. Additionally, LE8 score, health behavior score, and health factor score were used as categorical variables in the logistic regression models and a trend test was performed. The restricted cubic spline model was used for the dose–response analysis. Sensitivity analysis was used to test the robustness of the results. We excluded participants who had histories of CVD and perform multivariable logistic regression analysis to investigate the association between LE8 and its health behavior and health factors subscales. Additionally, propensity score matching (PSM) was used to reduce selection bias in observational studies. All statistical analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and a two-sided P < 0.05 was considered statistically significant.
Ethical approval
The data in this study were publicly available on the NHANES website. All procedures involving human participants were approved by the National Center for Health Statistics Research Ethics Review Committee, and all participants signed informed consent forms. This study complied with guidelines for cross-sectional studies outlined in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)23. NHANES is a survey designed to examine the health and nutritional status of the population in US involving interviews and physical examinations. Each cycle is independent with different individuals recruited and signed informed consent was obtained from every participant.
Results
Participants characteristics
The demographic characteristics of 5999 participants were included. A flowchart of the study selection is shown in Fig. 1 and baseline characteristics of participants are presented in Table 1. The weighted mean age of the study population was 39.44 (95% CI 39.18–39.70) years, and 3177 were female (52.96%) and participants with sarcopenia were significantly older than the nonsarcopenic (mean 39.19 vs 42.69 y; P < 0.0001). The mean LE8 score was 71.25 and the percentages of low, moderate, and high CVH were 8.45%, 62.96%, and 28.59% separately. LE8 score, HEI 2015 total score, health behavior score and health factor score were significantly lower of people with sarcopenia than the non-sarcopenia. For the LE8 elements, diet score had the least mean score of 37.31, whereas blood glucose score had the highest mean score of 90.04. Except for nicotine exposure score and sleep health score, there were statistically significant differences with lower means across all the 8 LE8 components’ scores for sarcopenia status. Besides, participants with sarcopenia had lower PIR and education levels, and higher values of age, and BMI, and incidence of hypertension, coronary heart disease, and diabetes compared to those without sarcopenia.
Association between LE8 score and sarcopenia
The ORs (95% CIs) for the associations between LE8 and the risk of sarcopenia are displayed in Table 2. Compared with low CVH, there was a lower prevalence of sarcopenia in people with high CVH (OR, 0.08; 95% CI 0.05–0.13; P < 0.0001) and moderate CVH (OR, 0.39; 95% CI 0.28–0.55; P < 0.0001). After adjusting for age, race and gender, PIR, education levels, marital status, and home status, participants with high CVH (OR, 0.12; 95% CI 0.07–0.23; P < 0.0001) and moderate CVH (OR, 0.47; 95% CI 0.31–0.72; P < 0.001) still had a lower risk of sarcopenia than low CVH as before (P for trend < 0.0001). The adjusted OR of per 10 scores increase in LE8 score was 0.62 (95% CI 0.56–0.67; P < 0.0001). Accordingly, the association between LE8 and sarcopenia was nonlinear (P < 0.01) in the restricted cubic spline model in Fig. 2A. The minimal threshold for the beneficial association was 70.625 scores (estimate OR = 1).
Association between health behavior score and sarcopenia
Despite the not statistically significant differences in health behavior score strata (P > 0.05), especially after adjusting for the potential covariates, the incidence of sarcopenia in participants with high health behavior score was lower than low health behavior group. After adjusting for age, race and gender, PIR, education levels, marital status, and home status, participants with high (OR, 0.64; 95% CI 0.39–1.03; P = 0.06) and moderate health behavior score group (OR, 1.13; 95% CI 0.76–1.69; P = 0.53) still had a lower risk of sarcopenia than low CVH as before (P for trend = 0.033). In the multivariable regression analysis, the adjusted OR of per 10 scores increase in health behavior score was 0.92 (95% CI 0.85–0.98; P = 0.02). The association between health behavior score and sarcopenia was nonlinear (P < 0.01) in the restricted cubic spline model in Fig. 2B. The minimal threshold for the beneficial association was 70 scores (estimate OR = 1).
Association between health factor score and sarcopenia
The prevalence of sarcopenia was significantly different among the three strata of health behaviors. After adjusting for age, race and gender, PIR, education levels, marital status, and home status, participants with high (OR, 0.08; 95% CI 0.05–0.13; P < 0.0001) and moderate health behavior score group (OR, 0.37; 95% CI 0.25–0.57; P < 0.0001) still had a lower risk of sarcopenia than low CVH as before (P for trend < 0.0001). In the multivariable regression analysis, the adjusted OR of per 10 scores increase in health factor score was 0.64 (95% CI 0.59–0.69; P < 0.0001). The association between health factor score and sarcopenia was nonlinear (P < 0.01) in the restricted cubic spline model in Fig. 2C. The minimal threshold for the beneficial association was 75 scores (estimate OR = 1).
Subgroup and sensitivity analysis
Figure 3 shows the result of subgroup analysis. As is shown, after adjusting for age, race, gender, PIR, education level, marital status, and home status, age, smoking status, hypertension, diabetes and, PIR had not a significant interaction effect on the association between LE8 scores and its subscales scores and risk of sarcopenia. LE8 score, health behavior score, and health factor score were significantly negatively associated with sarcopenia in every group. We perform two sensitivity analyses to assess the association between LE8 and its health behavior and health factor subscales with sarcopenia. Considering the potential impact of CVD on LE8 metrics, we investigated the relationship using participants without CVD histories (including coronary heart disease, angina, heart attack, and stroke; n = 217). After excluding participants who had histories of CVD, the OR for per 10 score increase in LE8 score, health behavior score, and health factor score were 0.61 (95% CI 0.55–0.68), 0.91 (95% CI 0.84–0.98) and 0.64 (95% CI 0.59–0.69) separately. In addition, to reduce bias in case selection and clinical confounding factors, we perform propensity score matching to correct the confounding factors (age, race, gender, PIR, education levels, marital status, and home status) and remove bias due to all observed covariates between the sarcopenia and non-sarcopenia and the OR for per 10 score increase in LE8 score, health behavior score and health factor score were 0.59 (95% CI 0.51–0.69), 0.90 (95% CI 0.81–1.00) and 0.62 (95% CI 0.55–0.70), respectively. The results were still robust in sensitivity analyses (Table 3).
Discussion
This cross-sectional study found an inverse relationship between LE8 score and sarcopenia. The association was generally robust in sensitivity and subgroup analyses. In contrast to previous studies, this study analyzed data from the NHANES using multivariable regression analysis to assess the relationship between LE8 and sarcopenia in the US adult population. In addition, we addressed the dose–response analysis to reveal an inverse association between the LE8 score, health behavior score, and health factor score with sarcopenia in US adults. To our knowledge, no other studies have examined this specific relationship. The findings from this study suggested that a higher LE8 score was associated with a lower risk of sarcopenia.
Previous studies have reported that cardiovascular disease was associated with sarcopenia. A British prospective cohort study involving 4252 subjects showed that sarcopenia was associated with greater cardiovascular mortality and all-cause mortality24. A cross-sectional study with small sample sizes (n = 208) in Brazil reported that sarcopenia was associated with subclinical atherosclerosis and endothelial dysfunction25. And in a German cohort, sarcopenia was a frequent co-morbidity among patients with chronic heart failure26.
Although the mechanism between CVD and sarcopenia remains not fully understood, current evidence has proved that sarcopenia is significantly associated with the LE8 metrics27,28,29. Sarcopenia and CVD have a common pathogenesis and interaction. In terms of health behavior score, sleep health metric is an influence factor among the four metrics. A meta-analysis indicated that versus the reference category of sleep duration (6–8 h), highest category (more than 8 h) and lowest category of sleep duration (under 6 h) shared the same negative effect regarding increased risk of sarcopenia30, almost consistent with sleep health score for CVH. Besides, growing studies about developing effective approaches to counteract the effects of sarcopenia have demonstrated that physical activity has been well accepted to be a significantly effective strategy shown to alleviate sarcopenia31,32,33. According to previous literature, the relationship between physical activity and sarcopenia may be related to inflammation. Inflammation is a well-known factor contributing to sarcopenia progression34,35,36. In exercised muscle, inflammatory cytokines such as IL-6 recruit immune cells and produce IL-10 receptor antagonists decreasing inflammatory injury37. Meanwhile, physical activity retards the development of atherosclerosis38. Smoking is a well-established risk factor for CVD and several studies have identified smoking is also a risk factor for sarcopenia39,40 through impairing muscle protein41. Nutrition is generally accepted as an influencing factor of sarcopenia42,43.
In the matter of health factor score, obesity, a major risk factor for cardiovascular disease, is closely related to BMI and blood lipids (2 metrics of health factor score) which involves extensive adipose tissue that damages muscle homeostasis, resulting in muscle atrophy and regeneration capacity reduction44. Resistin has been considered a proinflammatory molecule that correlates with CVD, expressed by monocytes and macrophages infiltrating the adipose tissue45. In skeletal muscle, activation of Insulin receptor substrate-1 and -2 phosphorylation and Akt and AMP-activated protein kinase were impaired by resistin46. Adipose tissue has a negative effect on muscle. Diabetes is characterized by hyperglycemia which may lead to loss of skeletal muscle mass and function because of insulin resistance47,48. The results of insulin resistance lead to a decrease in protein synthesis, muscle glucose disposal, and an increase in protein degradation49,50. As for hypertension, a 5-year follow-up study performed by the National Center for Geriatrics and Gerontology Study of Geriatric Syndromes (NCGG–SGS) found that hypertension was associated with an increased mortality risk among people with sarcopenia51. There was a lower cytochrome c oxidase (COX) content in the old hypertensive muscle than in normotensive aging which may lead to rarefaction in the aged skeletal muscle capillary network52. Above all, it is a composite score of all the LE8 metrics that relate to sarcopenia and LE8 is a potential tool for the assessment of sarcopenia.
In our investigation, the dose–response relationships showed that LE8 score and health factor score significantly decreased in ORs associated with sarcopenia within the lower range of values and gradually stabilized within the higher range of values. However, the trend was different in the association between health behavior score and sarcopenia. In the low range of health behavior score (value < 70), health behavior score in ORs associated with sarcopenia nearly remain unchanged with the lower range of values and decreased drastically in the higher range of values. A saturation effect was observed in the association between health factor score and sarcopenia, while it was not observed in health behavior score, indicating that stricter health behavior standards may be more desirable. There was no interaction among groups (p for interaction ≥ 0.05) in subgroup analyses which indicated the negative association between LE8 score and sarcopenia was stable in different groups.
There are some potential limitations in this study. First, the current study only included the US population and additional research is required to confirm whether the findings can be generalized to the non-US population. Second, because of the limitations of the NHANES database, our data on health behavior metrics were from self-reported questionary which may be subject to recall bias. Third, residual confounding effects could not be excluded due to measurement errors and unmeasured variables. Fourth, the definition of sarcopenia has different criteria and we used Foundation for the National Institutes of Health (FNIH) criteria which lack functional parameters such as grip strength or gait speed. Finally, as a cross-sectional analysis, the causal relationship between LE8 score and sarcopenia could not be determined in the study. Future longitudinal studies or more sophisticated analytical methods are required to advance our knowledge of this causality.
Despite the limitations mentioned above, this study had several strengths. First, to the best of our knowledge, this is the first study to explore the association between LE8 and sarcopenia. Second, our data using a study sample from the NHANES was relatively large, reliable, and, nationwide. Third, strict inclusion and exclusion criteria were performed and we used propensity score matching and dose–response analysis to measure the stability of results and identified the minimal threshold for the beneficial association.
Conclusion
In our study, we established an inverse relationship between LE8 and sarcopenia in an adult American population. Our findings suggest that LE8 is a potentially beneficial evaluation criterion for the risk of sarcopenia.
Data availability
The data in this study were publicly available on the NHANES official website (http://www.cdc.gov/nchs/nhanes.htm).
References
Bischoff-Ferrari, H. A. et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos. Int. 26, 2793–2802 (2015).
Schaap, L. A., Van Schoor, N. M., Lips, P. & Visser, M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: The longitudinal aging study Amsterdam. J. Gerontol. Ser. A 73, 1199–1204 (2018).
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L. & Morley, J. E. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J. Cachexia Sarcopenia Muscle 7, 28–36 (2016).
Choi, K. M. Sarcopenia and sarcopenic obesity. Korean J. Intern. Med. 31, 1054 (2016).
Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y. & Bruyère, O. Health outcomes of sarcopenia: A systematic review and meta-analysis. PloS one 12, e0169548 (2017).
Casati, M. et al. The biological foundations of sarcopenia: Established and promising markers. Front. Med. 6, 184 (2019).
Curcio, F. et al. Biomarkers in sarcopenia: A multifactorial approach. Exp. Gerontol. 85, 1–8 (2016).
Rooyackers, O. E., Adey, D. B., Ades, P. A. & Nair, K. S. Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. Proc. Natl. Acad. Sci. 93, 15364–15369 (1996).
Jin, H. et al. Unveiling genetic variants for age-related sarcopenia by conducting a genome-wide association study on Korean cohorts. Sci. Rep. 12, 3501 (2022).
Wong, H. J., Harith, S., Lua, P. L. & Ibrahim, K. A. Possible sarcopenia and its association with nutritional status, dietary intakes, physical activity and health-related quality of life among older stroke survivors. Ann. Geriatr. Med. Res. 26, 162 (2022).
Seo, J. H. & Lee, Y. Association of physical activity with sarcopenia evaluated based on muscle mass and strength in older adults: 2008–2011 and 2014–2018 Korea National Health and Nutrition Examination Surveys. BMC Geriatr. 22, 1–17 (2022).
Shaw, S., Dennison, E. & Cooper, C. Epidemiology of sarcopenia: Determinants throughout the lifecourse. Calcif. Tissue Int. 101, 229–247 (2017).
Bone, A. E., Hepgul, N., Kon, S. & Maddocks, M. Sarcopenia and frailty in chronic respiratory disease: Lessons from gerontology. Chronic Respir. Dis. 14, 85–99 (2017).
Chang, K.-V., Hsu, T.-H., Wu, W.-T., Huang, K.-C. & Han, D.-S. Association between sarcopenia and cognitive impairment: A systematic review and meta-analysis. J. Am. Med. Dir. Assoc. 17, 1164.e1167-1164.e1115 (2016).
Bahat, G. & Ilhan, B. Sarcopenia and the cardiometabolic syndrome: A narrative review. Eur. Geriatr. Med. 7, 220–223 (2016).
Gao, K. et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: Findings from the China health and retirement longitudinal study. EClinicalMedicine 44 (2022).
Sasaki, K.-I. et al. The prevalence of sarcopenia and subtypes in cardiovascular diseases, and a new diagnostic approach. J. Cardiol. 76, 266–272 (2020).
Lloyd-Jones, D. M. et al. Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation 146, e18–e43 (2022).
Krebs-Smith, S. M. et al. Update of the healthy eating index: HEI-2015. J. Acad. Nutr. Dietet. 118, 1591–1602 (2018).
Cawthon, P. M. et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 69, 567–575 (2014).
Chen, W. et al. Association of sarcopenia with ideal cardiovascular health metrics among US adults: A cross-sectional study of NHANES data from 2011 to 2018. BMJ Open 12, e061789 (2022).
Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people. Age Ageing 39, 412–423. https://doi.org/10.1093/ageing/afq034 (2010).
Von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370, 1453–1457 (2007).
Atkins, J. L. et al. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men. J. Am. Geriatr. Soc. 62, 253–260 (2014).
Campos, A. M., Moura, F. A., Santos, S. N., Freitas, W. M. & Sposito, A. C. Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly. Atherosclerosis 258, 138–144 (2017).
Fülster, S. et al. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur. Heart J. 34, 512–519 (2013).
Gao, Q. et al. Associated factors of sarcopenia in community-dwelling older adults: A systematic review and meta-analysis. Nutrients 13, 4291 (2021).
Shen, Y. et al. Prevalence and associated factors of sarcopenia in nursing home residents: A systematic review and meta-analysis. J. Am. Med. Dir. Assoc. 20, 5–13 (2019).
Anagnostis, P. et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and meta-analysis. Calcif. Tissue Int. 107, 453–463 (2020).
Pourmotabbed, A. et al. Sleep duration and sarcopenia risk: A systematic review and dose-response meta-analysis. Sleep Breath. 24, 1267–1278 (2020).
Lo, J.H.-T., Yiu, T., Ong, M.T.-Y. & Lee, W.Y.-W. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J. Orthopaed. Transl. 23, 38–52 (2020).
Pedersen, B. K. & Saltin, B. Exercise as medicine-evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sports 25, 1–72 (2015).
Dent, E. et al. International clinical practice guidelines for sarcopenia (ICFSR): Screening, diagnosis and management. J. Nutr. Health Aging 22, 1148–1161 (2018).
Tuttle, C. S., Thang, L. A. & Maier, A. B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res. Rev. 64, 101185 (2020).
Bano, G. et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas 96, 10–15 (2017).
Shi, L., Zhang, L., Zhang, D. & Chen, Z. Association between systemic immune-inflammation index and low muscle mass in US adults: A cross-sectional study. BMC Public Health 23, 1–9 (2023).
Maynard, C. L. & Weaver, C. T. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol. Rev. 226, 219–233 (2008).
Gleeson, M. et al. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11, 607–615 (2011).
Locquet, M., Bruyère, O., Lengelé, L., Reginster, J.-Y. & Beaudart, C. Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health 193, 101–108 (2021).
Rom, O., Kaisari, S., Aizenbud, D. & Reznick, A. Z. Sarcopenia and smoking: A possible cellular model of cigarette smoke effects on muscle protein breakdown. Ann. N. Y. Acad. Sci. 1259, 47–53 (2012).
Petersen, A. M. W. et al. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am. J. Physiol.-Endocrinol. Metab. (2007).
Ganapathy, A. & Nieves, J. W. Nutrition and sarcopenia—What do we know?. Nutrients 12, 1755 (2020).
Kakehi, S. et al. Rehabilitation nutrition and exercise therapy for sarcopenia. World J. Men’s Health 40, 1 (2022).
Batsis, J. A. & Villareal, D. T. Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nat. Rev. Endocrinol. 14, 513–537 (2018).
Butler, J. et al. Serum resistin concentrations and risk of new onset heart failure in older persons: The health, aging, and body composition (Health ABC) study. Arterioscler. Thromb. Vasc. Biol. 29, 1144–1149 (2009).
Satoh, H. et al. Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J. Clin. Invest. 114, 224–231 (2004).
Kim, T. N. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 33, 1497–1499 (2010).
Izzo, A., Massimino, E., Riccardi, G. & Della Pepa, G. A narrative review on sarcopenia in type 2 diabetes mellitus: Prevalence and associated factors. Nutrients 13, 183 (2021).
Pereira, S., Marliss, E. B., Morais, J. A., Chevalier, S. & Gougeon, R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 57, 56–63. https://doi.org/10.2337/db07-0887 (2008).
Liu, J. & Liu, Z. Muscle insulin resistance and the inflamed microvasculature: Fire from within. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20030562 (2019).
Yamaguchi, R. et al. Association of sarcopenia and systolic blood pressure with mortality: A 5-year longitudinal study. Arch. Gerontol. Geriatr. 110, 104988 (2023).
He, N., Zhang, Y., Zhang, L., Zhang, S. & Ye, H. Relationship between sarcopenia and cardiovascular diseases in the elderly: An overview. Front. Cardiovasc. Med. 8, 743710 (2021).
Funding
The study was supported by the High-level Talent Special Fund of the Minhang District of Shanghai (File No. 5-1).
Author information
Authors and Affiliations
Contributions
FL and SZ contributed to the conception and design of the study, and FL collected and analyzed the data. YD contributed to the revision of the manuscript. All authors approved the submitted version and agreed with the order of presentation of the authors.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Long, F., Zou, S. & Dong, Y. Associations between life’s essential 8 and sarcopenia in US adults: a cross-sectional analysis. Sci Rep 14, 9071 (2024). https://doi.org/10.1038/s41598-024-59421-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-59421-9
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.